Skip to main content

Major Depressive Disorder

March 26, 2020
After a Breakthrough Therapy guidance meeting with the US Food & Drug Administration (FDA), Sage Therapeutics announced plans to launch 3 additional studies of its investigational drug zuranolone.
February 24, 2020
    AXS-05, an investigational modulated-delivery tablet, significantly improved symptoms of depression
February 14, 2020
Researchers have developed a machine learning algorithm that uses electroencephalogram (EEG) data to predict whether a selective serotonin reuptake inhibitor (SSRI) is likely to benefit a patient.
January 24, 2020
An interactive voice application’s assessment of patient well-being through analysis of their speech was highly comparable with physicians’ tracking of patient well-being, according to a study published online in PLOS One.
January 21, 2020
Resting-state electroencephalographic (EEG) data may help in predicting the outcome of escitalopram treatment in patients with major depressive disorder (MDD), suggests a study published online in JAMA Network Open.
January 20, 2020
Psych Congress Steering Committee member Vladimir Maletic, MD, MS, discusses how frequently patients can cycle between depression and mania.
January 15, 2020
Knowing someone with emotional or mental health problems increased the likelihood that people who screened positive for depression sought out depression treatment for themselves, according to a study published online in Psychiatric Services.
December 17, 2019
Although the prevalence of cannabis use in the United States grew among people with and without depression between 2005 and 2017, in 2017 cannabis use was twice as common among people with depression.
December 17, 2019
Having a parent with depression was associated with structural differences in the brains of 9- and 10-year-olds, according to a study published online in the Journal of the American Academy of Child & Adolescent Psychiatry.
November 26, 2019
The US Food and Drug Administration (FDA) recently granted Usona Institute, Madison, Wisconsin, the Breakthrough Therapy designation for psilocybin in the treatment of patients with major depressive disorder (MDD). The designation formalizes the FDA’s commitment to an efficient development program…
Back to Top